Raymond v. Boehringer Ingelheim Pharmaceuticals, Inc.

578 F. Supp. 2d 391, 2008 U.S. Dist. LEXIS 63952, 104 Fair Empl. Prac. Cas. (BNA) 401, 2008 WL 3893754
CourtDistrict Court, D. Connecticut
DecidedAugust 21, 2008
DocketCivil Action 3:06-cv-1362 (VLB)
StatusPublished
Cited by1 cases

This text of 578 F. Supp. 2d 391 (Raymond v. Boehringer Ingelheim Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Raymond v. Boehringer Ingelheim Pharmaceuticals, Inc., 578 F. Supp. 2d 391, 2008 U.S. Dist. LEXIS 63952, 104 Fair Empl. Prac. Cas. (BNA) 401, 2008 WL 3893754 (D. Conn. 2008).

Opinion

MEMORANDUM OF DECISION AND ORDER DENYING THE PLAINTIFF’S MOTION FOR SUMMARY JUDGMENT [DOC. #37] AND GRANTING IN PART AND DENYING IN PART THE DEFENDANT’S MOTION FOR SUMMARY JUDGMENT [DOC # 31]

VANESSA L. BRYANT, District Judge.

Before the court are the parties’ cross-motions for summary judgment. The plaintiff, Robert Raymond, brings this action against the defendant, Boehringer In-gelheim Pharmaceuticals, Inc. (“BIPI”), asserting that his forced retirement upon turning sixty five violated the Age Discrimination in Employment Act, 29 U.S.C. § 621 et seq. (“ADEA”), and the Connecticut Fair Employment Practices Act, Conn. Gen.Stat. § 46a-50 et seq. (“CFE-PA”), and constituted a breach of contract. Both parties filed a motion for summary judgment. For the reasons hereinafter set forth, Raymond’s motion for summary judgment is DENIED and BIPI’s motion for summary judgment is GRANTED in part and DENIED in part.

*393 I. Facts

The following facts on the record are undisputed unless noted otherwise. Raymond was born on October 29, 1939. He is a lawyer with a Ph.D. in organic chemistry who practiced intellectual property law, concentrating on pharmaceutical patents. BIPI is a pharmaceutical company with a center of operations in Ridgefield, Connecticut, and is a subsidiary of a German parent company. BIPI and its parent have affiliates in the United States and abroad.

On July 22, 1994, Raymond completed and signed a BIPI employment application that included the statement: “I understand that, if hired, my employment is ‘at will’.... I further understand that this ‘at will’ employment relationship may not be changed except by written agreement signed by both the President or Vice President of Personnel at [BIPI] and me.” [Doc. # 34-1, Ex. 1] Raymond does not. claim that his at will employment relationship changed. BIPI hired Raymond as its chief patent counsel, effective October 31, 1994, two days after his fifty-fifth birthday.

On his first day of work, Raymond countersigned BIPI’s letter offering him employment. The letter read, in part: “This letter represents the total understanding regarding [BIPIJ’s offer of conditions of employment. Your signature below acknowledges that this is the only statement that you have relied upon in making your decision.” [Doe. # 34-1, Ex. 2]

Raymond claims that during discussions with BIPI prior to reaching an employment agreement, he voiced concerns about available pension benefits, the number of years he would be required to work for those benefits to vest, and his ability to continue working for the company long enough to earn those benefits irrespective of his age. He further claims that, in response, BIPI employees assured Raymond that BIPI had an anti-discrimination policy and that he would be able to work indefinitely so long as his job performance was positive. That alleged assurance was not reduced to writing.

On July 15, 1998, Raymond signed an acknowledgment of receipt of BIPI’s employee guide of personnel policies. [Doc. # 34-1, Ex. 3] The acknowledgment of receipt reiterated that Raymond was an at will employee. The employee guide did not include a mandatory retirement provision applicable to executives upon turning sixty five.

As BIPI’s chief patent counsel, Raymond oversaw BIPI’s entire patent law group and reported directly to BIPI’s general counsel. The patent law group took the lead on securing patents for BIPI inventions and directing legal initiatives to protect those patents from infringement. Raymond advised other affiliates of BIPI’s German parent on patent law. He collaborated with outside counsel on patent litigation matters. In around 2000, Raymond began reporting informally to the German parent’s patent head.

On October 1, 2002, the month of his sixty third birthday, BIPI promoted Raymond to Vice President Intellectual Property. The promotion did not increase Raymond’s duties or responsibilities. The promotion proposal submitted to the German parent’s board of directors for approval stated that the chief patent counsel’s workload had increased significantly in recent years, and the tile of Vice President would be commensurate with the position’s duties and necessary for BIPI’s succession plans. “It is expected that Dr. Raymond would hold this title until his retirement in two years time. Prior to that time, our succession plan calls for recruitment of an external candidate for this position. Preliminary research indi *394 cates that, to be competitive, a vice president title will be required.” [Doc. #40, Ex. 3] Raymond claims he never saw the promotion proposal.

In early 2003, Raymond was asked to assist BIPI’s search for his potential successor as vice president and chief patent counsel. Raymond claims that he sought assurances from BIPI’s general counsel, Ursula Bartels, that he was not being forced to retire. He claims that Bartels responded that the attorney being hired constituted only a potential successor, and the search was nothing more than contingency planning.

On August 29, 2003, BIPI hired Michael Morris as an attorney in the patent group. Raymond claims that Morris began usurping his professional and managerial duties immediately upon arrival; and that Raymond’s direct reports began reporting to Morris instead of him. In an April 12, 2004, email, Bartels referred to Morris as the “de facto head of the department.” [Doc. # 40, Ex. 6] He claims that he was left with few professional responsibilities or managerial authority within his own department.

Morris claims that he did not formally assume any of Raymond’s duties until after Raymond retired. BIPI claims that several members of the patent law group continued reporting directly to Raymond until his retirement, that Raymond retained his role in hiring and firing members of the group, and that he continued to collaborate with outside counsel on patent litigation matters. In 2004, twelve separate subsidiaries of the German parent sought direction and advice from Raymond regarding their patents.

Raymond claims that he first hear of the existence of a mandatory retirement policy at BIPI in the Spring of 2004, from Bar-tels. He claims that he did not learn of the specifics of that policy until September 22, 2004, when he met with David Nurn-berger, vice president human resources, to discuss his retirement. At that meeting, Nurnberger informed Raymond that BIPI had a mandatory retirement policy for executives upon reaching the age of sixty five.

Following the meeting, Raymond told Nurnberger that he believed that the company’s age based retirement policy is illegal and provided copies of a court decision analyzing what Raymond believes to be a similar mandatory retirement policy for executives, Whittlesey v. Union Carbide Corp., 567 F.Supp. 1320 (S.D.N.Y.1983). He checked BIPI’s policy database and found no mandatory retirement policy. BIPI admits that its mandatory retirement policy had not yet been published at the time. On September 28, 2004, despite Raymond’s objections based on the Whittlesey

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Raymond v. Boehringer Ingelheim Pharmaceuticals, Inc.
653 F. Supp. 2d 151 (D. Connecticut, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
578 F. Supp. 2d 391, 2008 U.S. Dist. LEXIS 63952, 104 Fair Empl. Prac. Cas. (BNA) 401, 2008 WL 3893754, Counsel Stack Legal Research, https://law.counselstack.com/opinion/raymond-v-boehringer-ingelheim-pharmaceuticals-inc-ctd-2008.